MILLIPLEX^® Mouse CD8+ T Cell Panel

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 15 analytes in mouse serum, plasma, and cell culture supernatants.

Analytes included: sCD137, sFas, sFAS ligand, GM-CSF, Granzyme B, IFNγ, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1β, RANTES, TNF-α

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Save Time, Samples, and Budget: With just 25 µL of sample, you can measure up to 15 analytes—minimizing animal use and maximizing data output. This efficiency translates to faster results and lower costs per data point.

Unlock Deeper Insights into Immune Function: This panel is designed to decode the complexity of CD8+ T cell responses, giving researchers a powerful lens into cytotoxic activity, immune regulation, and inflammation—all in one assay

Trusted Performance with Proven Reproducibility: Built on the Luminex^® xMAP^® platform, this panel delivers high sensitivity, low variability, and robust reproducibility, ensuring confidence in every data set.

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells.